Lead Product(s) : SFA005
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : SFA Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Melior Discovery Announces Partnership with SFA on Grant Directed to COVID-19
Details : In this important effort to counter the effects of the COVID-19 virus SFA005 is expected to address the cytokine storm linked to Acute Respiratory Distress Syndrome (ARDS) experienced by patients infected with COVID-19.
Product Name : SFA005
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 24, 2020
Lead Product(s) : SFA005
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : SFA Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership